GYPA and COVID-19: The majority of EVs in COVID-19 patients originated from platelets (30.9 ± 17.6%, CD41+ EVs) followed by red blood cells (10.1 ± 7.1%, CD235a+ EVs) and leukocytes (9.4 ± 3.5%, CD45+ EVs).